Loading
Cardio-oncology builds heart risk assessment, monitoring and prevention into cancer care so patients can finish curative treatment without trading cancer for heart failure. It targets anthracycline and trastuzumab damage, checkpoint-inhibitor myocarditis and radiation heart disease using echocardiography, troponin tests and protective drugs; specialist clinics are concentrated in large centres.
Cardio-oncology integrates risk stratification, surveillance, and prevention of heart damage into cancer care, so that patients can complete curative therapy without trading cancer for heart failure. The problems it addresses include anthracycline and trastuzumab cardiotoxicity, checkpoint-inhibitor myocarditis, TKI hypertension and QT prolongation, and radiation heart disease. Tools are baseline and serial echocardiography with strain imaging, troponin and BNP monitoring, and cardioprotective drugs such as dexrazoxane, ACE inhibitors, and statins. As survivors live longer, cardiovascular disease becomes a leading competing cause of death, which is why the field has grown. Workforce and access are the limitations, since specialist clinics are concentrated in large centres. The simple version is protecting the heart while the cancer is being treated.
Risk stratification, surveillance, and prevention integrated into oncology care.
Dexrazoxane protects the heart from the cumulative damage of doxorubicin in women with metastatic breast cancer who need to keep receiving it, and, as Totect, limits tissue destruction when an anthracycline leaks out of a vein.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
Query for this technology: (TITLE:"cardio-oncology" OR ABSTRACT:"cardio-oncology" OR TITLE:"cardiotoxicity" OR ABSTRACT:"cardiotoxicity") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cardio-oncology, not a curated reading list.
Shares Cancer neuroscience: cutting the nerve supply, A survivorship research endowment funded by a levy on curative therapy prices, A dedicated programme for cachexia and treatment toxicity research, Cardiopulmonary exercise testing: the hardest number in recovery.
Shares The heart after anthracyclines and chest radiotherapy in childhood, Childhood Cancer Survivor Study (CCSS), Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it.
Shares A dedicated programme for cachexia and treatment toxicity research, Multinational Association of Supportive Care in Cancer, Cachexia, toxicity and the limits of the patient, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards.
Shares A survivor biobank to find who will develop late effects before they do, The heart after anthracyclines and chest radiotherapy in childhood, Childhood Cancer Survivor Study (CCSS), Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it.
Shares Cardiotoxicity (LVEF decline, cardiomyopathy), Strain echocardiography (global longitudinal strain), Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV).
Shares Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors, Doxorubicin, Survivorship and late effects are neglected, Hodgkin lymphoma.
Shares Intermediate-risk neuroblastoma, Adolescent and young adult cancers (ages 15 to 39), High-risk neuroblastoma, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards.
Shares Gary H. Lyman, A dedicated programme for cachexia and treatment toxicity research, Multinational Association of Supportive Care in Cancer, Paths to cures: interception, eradication, control.